Saturday, January 10, 2009

VU drug discovery, industry partnership

Vanderbilt University's deal with Janssen Pharmaceutica NV is initially worth $10 million in funding for the lab run by Jeffrey Conn (at left), director of VU's drug-discovery program. The target: schizophrenia. VU stands to earn more than the base by meeting or surpassing milestones and through royalties on product sales. Janssen is based in Beerse, in the Antwerp province of Belgium, with U.S. offices in Titusville, N.J.


No comments: